SCHEMBL3915520

SCHEMBL3915520

COC(=O)c1ccc(CN2C(=O)C(C(C)C)NC23CCN(C(=O)NCc2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.48
P2RY12 Q9H244 2/20 0.41
EPHX2 P34913 1/20 0.40
ERN1 O75460 1/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 4/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PTGES O14684 1/20 0.37
TAOK1 Q7L7X3 1/20 0.37
TAOK3 Q9H2K8 1/20 0.37
MAPK1 P28482 1/20 0.36
MDM2 Q00987 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
ENPP2 Q13822 1/20 0.35
CA12 O43570 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926266 0.83 MAPT (0.47) LMNAHTTNPC1RAB9AMDM2
SCHEMBL3919278 0.82 SLC6A3 (0.44) EPHX2
SCHEMBL3928978 0.81 LMNA (0.41) EPHX2TSHRLMNAHTTNPC1
SCHEMBL1799198 0.80 LMNA (0.39) LMNAHTTNPC1RAB9AMDM2
SCHEMBL3918951 0.80 LMNA (0.44) LMNAHTTNPC1RAB9AMDM2
SCHEMBL3918182 0.79 SMN1; SMN2 (0.47) TSHRLMNAHTTNPC1RAB9A
SCHEMBL3916498 0.79 GAA (0.44) LMNAHTTNPC1RAB9ASMN1; SMN2
SCHEMBL3927597 0.78 ALDH1A1 (0.48) LMNAHTTRAB9AMAPK1SMN1; SMN2
SCHEMBL3914913 0.77 GAA (0.41) LMNAHTTNPC1RAB9ASMN1; SMN2
SCHEMBL1799799 0.77 CYP2C19 (0.41) LMNAHTTNPC1RAB9AMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 HRH3 3686/4885P2RY12 3563/4885EPHX2 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.